US2012077835A1PendingUtilityA1

Formulations of rifaximin and uses thereof

49
Assignee: SELBO JONPriority: Jul 12, 2010Filed: Jul 12, 2011Published: Mar 29, 2012
Est. expiryJul 12, 2030(~4 yrs left)· nominal 20-yr term from priority
Inventors:Jon Gordon SelboJing TengMohammed A. KabirPam Golden
A61P 31/00A61P 31/04A61K 9/2027A61K 9/4858A61K 9/1641A61K 9/146A61K 9/4866A61K 9/1652A61K 47/32C07D 498/22A61K 9/2054A61K 47/38A61K 31/437A61K 9/10A61P 1/00
49
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to new rifaximin forms comprising solid dispersions of rifaximin, methods of making same and to their use in medicinal preparations and therapeutic methods.

Claims

exact text as granted — not AI-modified
1 . A form solid dispersion of rifaximin. 
     
     
         2 . The form according to  claim 1 , wherein the form solid dispersion of rifaximin is characterized by an XRPD substantially similar to one or more of the XRPDs of  FIGS. 2 ,  7 ,  12 ,  17 ,  22 ,  31 , and  36 . 
     
     
         3 . The form according to  claim 1 , wherein the form solid dispersion of rifaximin is characterized by a Thermogram substantially similar to  FIGS. 3-6 ,  8 - 11 ,  13 - 16 ,  18 - 21 ,  23 - 26 ,  27 - 30 , and  32 . 
     
     
         4 . The form according to of  claim 1 , wherein the form has the appearance of a single glass transition temperature (Tg). 
     
     
         5 . The form according to of  claim 1 , wherein a Tg of a form increases with an increased rifaximin concentration 
     
     
         6 . The form according to of  claim 1 , wherein a form stressed at 70° C./75% RH for 1 week, solids are still x-ray amorphous according to XRPD. 
     
     
         7 . The form according to of  claim 1 , wherein a form stressed at 70° C./75% RH for 3 weeks, solids are still x-ray amorphous according to XRPD. 
     
     
         8 . The form according to of  claim 1 , wherein a form stressed at 70° C./75% RH for 6 weeks, solids are still x-ray amorphous according to XRPD. 
     
     
         9 . The form according to of  claim 1 , wherein a form stressed at 70° C./75% RH for 12 weeks, solids are still x-ray amorphous according to XRPD. 
     
     
         10 . A microgranule comprising the solid dispersion form of rifaximin as described in  claim 1 . 
     
     
         11 . The microgranule of  claim 10 , further comprising a polymer. 
     
     
         12 . The microgranule of  claim 11 , wherein the polymer comprises one or more of polyvinylpyrrolidone (PVP) grade K-90, hydroxypropyl methylcellulose phthalate (HPMC-P) grade 55, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) grades HG and MG, or a polymethacrylate (Eudragit® L100-55). 
     
     
         13 . The microgranule of  claim 12 , wherein the microgranule comprises 25-75% polymer. 
     
     
         14 . The microgranule of  claim 13 , wherein the microgranule comprises 40-60% polymer. 
     
     
         15 . The microgranule of  claim 14 , wherein the microgranule comprises 40-50% polymer. 
     
     
         16 . The microgranule of  claim 15 , wherein the microgranule comprises 42-44% polymer. 
     
     
         17 . The microgranule of  claim 11 , wherein the microgranule comprises equal amounts of rifaximin and polymer. 
     
     
         18 . The microgranule of  claim 10 , further comprising an intragranular release controlling agent. 
     
     
         19 . The microgranule of  claim 18 , wherein the intragranular release controlling agent comprises between about 2 wt % to about 40 wt % of the microgranule. 
     
     
         20 . The microgranule of  claim 19 , wherein the intragranular release controlling agent comprises between about 5 wt % to about 20 wt % of the microgranule. 
     
     
         21 . The microgranule of  claim 20 , wherein the intragranular release controlling agent comprises about 10 wt % of the formulation. 
     
     
         22 . The microgranule of  claim 18 , wherein the intragranular release controlling agent comprises a pharmaceutically acceptable excepient. 
     
     
         23 . The microgranule of  claim 22 , wherein the intragranular release controlling agent comprises a pharmaceutically acceptable excepient, disintegrant, crosprovidone, sodium starch glycolate, corn starch, microcrystalline cellulose, cellulosic derivatives, sodium bicarbonate, and sodium alginate. 
     
     
         24 . The microgranule of  claim 10 , further comprising a surfactant. 
     
     
         25 . The microgranule of  claim 24 , wherein the surfactant is a non-ionic. 
     
     
         26 . The microgranule of  claim 25 , wherein the non-ionic surfactant comprises between about 2 wt % to about 10 wt % of the microgranule. 
     
     
         27 . The microgranule of  claim 26 , wherein the non-ionic surfactant comprises between about 4 wt % to about 8 wt % of the microgranule. 
     
     
         28 . The microgranule of  claim 27 , wherein the non-ionic surfactant comprises about 5.0 wt % of the microgranule. 
     
     
         29 . The microgranule of  claim 24 , wherein the non-ionic surfactant comprises a poloxamer. 
     
     
         30 . The microgranule of  claim 25 , wherein the poloxamer comprises poloxamer 407. 
     
     
         31 . The microgranule of  claim 10 , further comprising an antioxidant. 
     
     
         32 . The microgranule of  claim 31 , wherein the antioxidant is selected from the group consisting of butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and propyl gallate (PG). 
     
     
         33 . The microgranule of  claim 31 , wherein the antioxidant comprises between about 0.1 wt % to about 3 wt % of the microgranule. 
     
     
         34 . The microgranule of  claim 31 , wherein the antioxidant comprises between about 0.5 wt % to about 1 wt % of the microgranule. 
     
     
         35 . A pharmaceutical composition comprising the microgranule of  claim 10 . 
     
     
         36 . The pharmaceutical composition of  claim 35 , further comprising one or more pharmaceutically acceptable excepients. 
     
     
         37 . The pharmaceutical composition of  claim 35 , wherein the composition comprises a tablet or capsule. 
     
     
         38 . The pharmaceutical composition of  claim 37 , wherein the pharmaceutical composition comprises a disintegrant. 
     
     
         39 . A pharmaceutical composition comprising SD rifaximin, a polymer, a surfactant, and a release controlling agent. 
     
     
         40 . The pharmaceutical composition of  claim 39 , comprising SD rifaximin, HPMC-AS, pluronic F127, and croscarmellose Na (CS). 
     
     
         41 . The pharmaceutical composition of  claim 39 , wherein the pharmaceutical compositions are tablets or pills. 
     
     
         42 . The pharmaceutical composition of  claim 39 , further comprise fillers, glidants or lubricants. 
     
     
         43 . The pharmaceutical composition of  claim 40 , wherein the composition comprises the ratio of components set forth in Table 37. 
     
     
         44 . A process for producing a solid dispersion of rifaximin comprising:
 making a slurry of methanol, rifaximin, a polymer and a surfactant;   spray drying the slurry   
     
     
         45 . A process for producing a solid dispersion of rifaximin comprising:
 making a slurry of methanol, rifaximin, HPMC-AS MG and poloxamer 407; and   spray drying the slurry.   
     
     
         46 . A process for producing form solid dispersion of rifaximin comprising one or more of the methods listed in Tables 1, 5 or 9.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.